Molecular Imaging in Oncology Models Using Small Animals
Small Animal Imaging is revolutionizing oncology research by enabling molecular-level visualization of cancer in preclinical models. Molecular imaging allows scientists to study tumor biology, monitor treatment response, and evaluate novel therapeutics in vivo.
Fluorescence and bioluminescence imaging are widely used to track tumor growth and gene expression in live animals. Radiotracer-based PET imaging provides complementary functional data, revealing metabolic activity, receptor expression, and angiogenesis within tumors. The combination of these modalities enables a more comprehensive understanding of cancer progression and therapeutic efficacy.
Recent advancements in molecular probes and contrast agents have improved specificity and sensitivity. For example, antibody-based probes and targeted nanoparticles can selectively bind to tumor cells or microenvironment components, enabling precise visualization and quantification of cancerous lesions.
Integration with AI-based analysis tools has enhanced the interpretation of complex molecular imaging datasets. Researchers can automatically segment tumors, quantify changes over time, and identify early indicators of treatment response. This capability accelerates preclinical studies and provides actionable insights for translational research.
By combining high-resolution imaging, molecular targeting, and advanced analytics, small animal models have become indispensable in oncology research. These innovations not only improve the predictive accuracy of preclinical studies but also facilitate the development of personalized cancer therapies that are more likely to succeed in clinical trials.